Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Legnano – page 28

2 907 clinical trials in Legnano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Legnano at a glance
2 907
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 907 trials in Legnano

Open in trial search

Small cell lung cancer

Recruiting

A study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Abbvie Deutschland GmbH & Co. KG

Neoplasm malignant

Recruiting

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.

A study to evaluate the effect of zigakibart in adults with IgA nephropathy

Recruiting
InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Chronic lymphocytic leukaemia

Recruiting

A study of emavusertib and zanubrutinib in patients with chronic lymphocytic leukemia and other B-cell cancers.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Emavusertib
  • Sponsor:Curis Inc.

Duchenne muscular dystrophy

Recruiting

A study to evaluate the long-term safety and effectiveness of BMN 351 in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:BMN 351
  • Sponsor:Biomarin Pharmaceutical Inc.

Interstitial lung disease+1

Recruiting

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Liquidia Technologies Inc.

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Mantle cell lymphoma recurrent+1

Recruiting

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Hormone-refractory prostate cancer

Recruiting

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Janssen Cilag International

Angelman's syndrome

Recruiting

A Phase 3 study to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Sponsor:Ionis Pharmaceuticals Inc.

Thrombotic thrombocytopenic purpura+1

Recruiting

A study to evaluate the safety and effectiveness of urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor in patients with immune-mediated thrombotic thrombocytopenic purpura.

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Urokinase, catalytic domain, fused with a single-chain antibody against VON willebrand factor
  • Sponsor:TargED Biopharmaceuticals B.V.

Hormone-refractory prostate cancer+1

Recruiting

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Legnano

What the registry says about research in the country

01 Hematologic Oncology

Extensive research focusing on Multiple Myeloma treatments, including innovative therapies for relapsed and refractory cases. Studies evaluating new drug combinations and treatment approaches for better patient outcomes.

  • Melflufen therapy for elderly patients
  • Elranatamab monotherapy trials
  • Novel combination treatments for RRMM

Multiple ongoing trials testing various therapeutic combinations to improve survival rates.

02 Solid Tumors

Groundbreaking studies in lung cancer and breast cancer treatment, investigating novel immunotherapy combinations and targeted therapies.

  • Advanced NSCLC immunotherapy trials
  • HER2-positive breast cancer treatments
  • Colorectal cancer targeted therapies

Focus on personalized treatment approaches and biomarker-driven therapies.

03 Chronic Conditions

Innovative research in chronic kidney disease and HIV management, exploring new treatment strategies and medication combinations.

  • Non-diabetic kidney disease treatments
  • HIV antiretroviral therapy optimization
  • Ulcerative colitis interventions

Studies aimed at improving long-term patient outcomes and quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.